Art

J-GLOBAL ID：201702245806410279   Reference number：17A0617315

Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

エストロゲン受容体陽性HER2陰性乳癌の早期および晩期遠隔再発患者における再発後生存率

Author (17)： OGIYA Akiko (Cancer Inst. Hospital, Tokyo, JPN) ,  YAMAZAKI Kieko (Cancer Inst. Hospital, Tokyo, JPN) ,  HORII Rie (Cancer Inst. Japanese Foundation for Cancer Res., Tokyo, JPN) ,  SHIEN Tadahiko (Okayama Univ. Hospital, Okayama, JPN) ,  HORIMOTO Yoshiya (Juntendo Univ. School of Medicine, Tokyo, JPN) ,  MASUDA Norikazu (Osaka National Hospital, Osaka, JPN) ,  INAO Touko (Kumamoto Univ., Kumamoto, JPN) ,  HOSODA Mitsuchika (Hokkaido Univ., Hospital, Sapporo, JPN) ,  ISHIDA Naoko (Hokkaido Univ., Hospital, Sapporo, JPN) ,  OSAKO Tomofumi (Kumamoto City Hospital, Kumamoto, JPN) ,  OSAKO Tomofumi (Kumamoto Shinto General Hospital, Kumamoto, JPN) ,  TAKAHASHI Masato (Hokkaido Cancer Center, Sapporo, JPN) ,  ENDO Yumi (Nagoya City Univ. Graduate School of Medical Sci., Nagoya, JPN) ,  MIYOSHI Yuichiro (Okayama Univ. Hospital, Okayama, JPN) ,  YASOJIMA Hiroyuki (Osaka National Hospital, Osaka, JPN) ,  TOMIOKA Nobumoto (Hokkaido Cancer Center, Sapporo, JPN) ,  YAMASHITA Hiroko (Hokkaido Univ., Hospital, Sapporo, JPN)
Material： Breast Cancer
Volume： 24  Issue： 3  Page： 473-482  Publication year： May. 2017 
JST Material Number： L3971A  ISSN： 1340-6868  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： Her2 negative breast cancer ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0617315&from=J-GLOBAL&jstjournalNo=L3971A") }}

JST classification (1)： Treatment for gynecologic and obstetrical diseases in general  (GS05010C)

Reference (22)：

• Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 2011;29:2301-4.
• Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738-46.
• Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26:1948-55.
• Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007;99:1845-53.
• Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381:805-16.

Terms in the title (6)： エストロゲン受容体陽性HER2陰性乳癌 ,  早期 ,  遠隔再発 ,  患者 ,  再発 ,  生存率